Wall Street brokerages forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report $26.90 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $17.10 million and the highest estimate coming in at $42.38 million. Alnylam Pharmaceuticals posted sales of $17.45 million in the same quarter last year, which suggests a positive year over year growth rate of 54.2%. The company is expected to issue its next quarterly earnings results on Wednesday, February 14th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year sales of $26.90 million for the current fiscal year, with estimates ranging from $56.59 million to $94.36 million. For the next fiscal year, analysts forecast that the firm will report sales of $102.43 million per share, with estimates ranging from $13.74 million to $137.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million during the quarter, compared to analyst estimates of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The company’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.21) EPS.
ALNY has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Jefferies Group LLC set a $102.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. BidaskClub downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 16th. Credit Suisse Group reaffirmed a “buy” rating and issued a $96.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, August 11th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $56.00 target price (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $121.85.
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $132.85 on Monday. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.
In other news, President Barry E. Greene sold 76,815 shares of the stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the transaction, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 73,415 shares of the stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total value of $9,610,023.50. Following the completion of the transaction, the chief executive officer now owns 223,125 shares of the company’s stock, valued at $29,207,062.50. The disclosure for this sale can be found here. Insiders sold a total of 363,212 shares of company stock valued at $44,032,736 over the last quarter. 4.30% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in ALNY. Public Employees Retirement System of Ohio raised its position in Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 32,880 shares of the biopharmaceutical company’s stock worth $3,863,000 after purchasing an additional 1,026 shares during the last quarter. Security National Bank of SO Dak bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $247,000. California Public Employees Retirement System raised its position in Alnylam Pharmaceuticals by 5.1% during the 3rd quarter. California Public Employees Retirement System now owns 133,206 shares of the biopharmaceutical company’s stock worth $15,650,000 after purchasing an additional 6,506 shares during the last quarter. Virtu Financial LLC bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $286,000. Finally, Orbimed Advisors LLC raised its position in Alnylam Pharmaceuticals by 69.7% during the 3rd quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after purchasing an additional 445,600 shares during the last quarter. Institutional investors own 86.04% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.